摘要
目的探讨对化疗后血小板减少症患者联合应用升板方与重组人白介素-11治疗的效果。方法选择2019年3月-2021年2月本院接受化疗后出现血小板减少症的患者56例,按照随机数字表法分为联合组和对照组,各28例。对照组给予重组人白介素-11治疗,联合组在对照组的基础上加用升板方治疗,比较两组血小板计数(PLT)、凝血功能改善情况、治疗效果及不良反应发生率。结果治疗7 d、14 d后,两组SPC均高于治疗前,联合组高于对照组(P<0.05);联合组的SPC≤30×109/L、SPC≥75×109/L持续时间均较对照组短(P<0.05);治疗14 d后,两组FIB水平较治疗前上升,PT、APTT、TT较治疗前下降;且联合组FIB水平高于对照组,PT、APTT、TT水平低于对照组(P<0.05);联合组的治疗有效率为89.29%,略高于对照组的71.43%,但差异无统计学意义(P>0.05);联合组用药后不良反应发生率为7.14%,较对照组的17.86%低,但差异无统计学意义(P>0.05)。结论联合应用升板方与重组人白介素-11治疗化疗后血小板减少症效果确切,可控制病情进展,促进血小板计数恢复正常,还可调节机体凝血功能,且用药后不良反应发生率低,治疗安全性高。
Objective To explore the effect of combining Shengbanfang and recombinant human interleukin-11 in the treatment of thrombocytopenia after chemotherapy.Methods A total of 56 patients with thrombocytopenia after chemotherapy in our hospital from March 2019 to February 2021 were randomly divided into combined group and control group,with 28 cases in each group.The control group was treated with recombinant human interleukin-11,and the combined group was treated with Shengban decoction on the basis of the control group.The platelet count(PLT),improvement of coagulation function,therapeutic effect and incidence of adverse reactions were compared between the two groups.Results After 7 d and 14 d of treatment,the SPC of the two groups were higher than those before treatment,and the combined group was higher than the control group(P<0.05).The duration of SPC≤30×109/L and SPC≥75×109/L in the combined group were shorter than those in the control group(P<0.05).After 14 days of treatment,the level of FIB in the two groups were higher than those before treatment,the levels of PT,APTT and TT were lower than those before treatment,the level of FIB in the combined group was higher than that in the control group,and the levels of PT,APTT and TT were lower than those of the control group(P<0.05).The effective rate of the combined group was 89.29%,which was slightly higher than 71.43%of the control group,but the difference was not statistically significant(P>0.05).The incidence of adverse reactions in the combined group was 7.14%,which was lower than 17.86%in the control group,but the difference was not statistically significant(P>0.05).Conclusion The combined application of Shengbanfang and recombinant human interleukin-11 in the treatment of thrombocytopenia after chemotherapy is effective,which can control the progression of the disease,promote the recovery of platelet count,and regulate the coagulation function of the body.The incidence of adverse reactions after treatment is low,and the treatment safety is high.
作者
陈海燕
翟长云
王伟奇
朱蓉蓉
沈洋
王晋秋
CHEN Hai-yan;ZHAI Chang-yun;WANG Wei-qi;ZHU Rong-rong;SHEN Yang;WANG Jin-qiu(Department of Oncology,Dafeng People's Hospital,Yancheng 224100,Jiangsu,China)
出处
《医学信息》
2022年第3期172-174,共3页
Journal of Medical Information
关键词
化疗
血小板减少症
升板方
重组人白介素-11
凝血功能
血小板计数
Chemotherapy
Thrombocytopenia
Shengbanfang
Recombinant human interleukin-11
Coagulation function
Platelet count
